World-Class Scientists
Our Scientists and Researchers have proven experience in the production of human basic Fibroblast Growth Factor (hbFGF) as well as the production of all the 23 known Fibroblast Growth Factors including hbFGF and Epidermal Growth Factor.
Our scientists have also discovered a method to produce hbFGF and EGF for a much lower price than the typical cost of hbFGF which as of 9 June 2022 costs AU$ 17 million. and EGF costs from AU$ 1.5 million per gram.
Our scientists have also discovered a way to produce Fibroblast Growth Factors and valuable proteins bio-identical, which makes our Growth Factors identical to the signaling proteins in your own body.
WoundFactor
Basic Fibroblast Growth Factor in Scarless Wound Healing by S Akita - 2013 - Cited by 78 - Related articles
WoundFactor wound healing Cream
Scientists at Universal Medical Research Pty Ltd (UMR) have developed a topical application which contains hbFGF and EGF for the treatment of Diabetic Ulcers, Pressure wounds and other hard to heal wounds. We are currently inviting interested Medical Practitioners to trial our wound healing products.
Advances in surgical applications of growth factors for wound healing April 5, 2019 by S Yamakawa - Cited by 18 - Related articles of the FGF family, bFGF has been the protein of choice for improving wound healing outcomes in humans.
According to a study performed by Ann Surg in 1992 Diabetes mellitus comprises a multiple metabolic disorder that affects millions of people worldwide and consequentially poses challenges for clinical treatment.
Among the various complications, diabetic ulcer constitutes the most prevalent associated disorder and leads to delayed wound healing.
Our results indicate that an HDC matrix loaded with 0.3 μg/cm2 ST-EGF or 1 μg/cm2 ST-bFGF can promote wound healing in diabetic ulcers and are suitable for use in wound dressings owing to their stability for long periods at room temperature. Credit to Ann Surg. 1992 Oct; 216(4): 401–408
The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores Ann Surg. 1992 Oct; 216(4): 401–408
Statement of Significance
VAnn Surg also reported in her research paper that:” various types of dressing materials loaded with growth factors, such as VEGF, EGF, and bFGF, are widely used to effect wound repair. However, such growth factor-loaded materials have several limitations for use as therapeutic agents in healing-impaired diabetic wounds.
To overcome these limitations, we have developed new materials containing structurally stabilized EGF (ST-EGF) and bFGF (ST-bFGF). To confirm the wound healing capacity of newly developed materials (ST-EGF and ST-bFGF-loaded hyaluronate-collagen dressing [HCD] matrix), we applied these matrices in type I and type II diabetic wounds.
Notably, these matrices were able to accelerate wound healing including re-epithelialization, neovascularization, and collagen deposition. Consequentially, these ST-EGF and ST-bFGF-loaded HCD matrix may be used as future therapeutic agents in patients with diabetic foot ulcers”.
